EXAS - EXACT SCIENCES CORP
IEX Last Trade
57.54
0.010 0.017%
Share volume: 28,173
Last Updated: Thu 26 Dec 2024 08:30:04 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$57.53
0.01
0.02%
Fundamental analysis
8%
Profitability
0%
Dept financing
35%
Liquidity
38%
Performance
1%
Performance
5 Days
-1.39%
1 Month
-3.31%
3 Months
-14.47%
6 Months
31.59%
1 Year
-23.19%
2 Year
15.18%
Key data
Stock price
$57.54
DAY RANGE
$57.32 - $58.56
52 WEEK RANGE
$41.92 - $79.62
52 WEEK CHANGE
-$23.26
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/30/2024
Company detail
CEO: Kevin T. Conroy
Region: US
Website: exactsciences.com
Employees: 6,400
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: exactsciences.com
Employees: 6,400
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Exact Sciences Corporation provides cancer screening and diagnostic test products. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers.
Recent news